-
03
2026
2026.03.31 -
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
Preclinical research on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association’s 2026 Scientific Sessions.The presentation will be delivered by W. Timothy Garvey, MD, a globally recognized authority in obesity and metabolic medicine and a scientific advisor to Caliway.
-
03
2026
2026.03.19 -
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
Preclinical data on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for oral presentation at the European Congress on Obesity (ECO 2026). The presentation will be delivered by Arya M. Sharma, MD, Caliway’s scientific advisor and a globally recognized authority in obesity medicine, who will discuss CBL-514’s fat-reduction efficacy, differentiated mechanism, and potential scientific value as a complementary approach to current weight-loss therapies.
-
02
2026
2026.02.23 -
Caliway Completes Australian HREC Submission for CBL-0206, Advancing Asia-Pacific Clinical Strategy
CBL-0206 Phase 2 study of Caliway’s first-in-class large-area localized fat reduction drug, CBL-514, has completed Australian HREC submission. The study will be conducted in Taiwan and Australia, with an estimated enrollment of approximately 250 participants. The study aims to expand safety and efficacy data in Asian populations, supporting future NDA filings and Caliway’s global and regional dual-track licensing strategy
